title: Mechanism of polymorphonuclear leukocytes accumulation examined using inhibitors of complement and arachidonic acid cascade in rats treated with OK-432.
abstract: When the streptococcal preparation OK-432 was intraperitoneally injected for the treatment of carcinomatous peritonitis, antitumor polymorphonuclear leukocytes (PMNs) accumulated in the peritoneal cavity. We examined the mechanism of this PMN accumulation using an in vivo system in rats. FUT-175, EDTA and K76 inhibited C5a generation by OK-432 in vitro, but EGTA, prednisolone and inhibitors of arachidonic acid cascade did not. In in vivo experiments, EDTA, FUT-175, antirat C3 serum and K76 reduced the accumulation of PMNs onto filter membranes, when these reagents were reacted with OK-432 for 3 h through filter membranes placed on the turned rat peritoneum. EGTA failed to inhibit PMN accumulation. Prednisolone, indomethacin, OKY046 and AA861 inhibited PMN accumulation in a dose-dependent manner. These inhibitions of PMN accumulation were confirmed by histological examination. It was concluded that complement-derived chemotactic factor C5a generated by OK-432 induced PMN accumulation in association with chemotactic arachidonic acid metabolites.
authors.affiliation: First Department of Internal Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kato
authors.forename: M
authors.initials: M
authors.lastname: Inoue
authors.forename: Y
authors.initials: Y
authors.lastname: Yamamura
authors.forename: M
authors.initials: M
authors.lastname: Tanigawa
authors.forename: H
authors.initials: H
authors.lastname: Sano
authors.forename: S
authors.initials: S
authors.lastname: Sugino
authors.forename: M
authors.initials: M
authors.lastname: Kondo
mesh_terms: D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism*; D001550:Benzamidines; D016227:Benzoquinones; D001688:Biological Products / Q000494:pharmacology*; D002452:Cell Count; D002630:Chemotactic Factors / Q000378:metabolism*; D015936:Complement C5a / Q000378:metabolism*; D003169:Complement Inactivator Proteins / Q000494:pharmacology*; D004492:Edetic Acid / Q000494:pharmacology; D004533:Egtazic Acid / Q000494:pharmacology; D006146:Guanidines / Q000494:pharmacology; D006801:Humans; D008297:Male; D008689:Methacrylates / Q000494:pharmacology; D009504:Neutrophils / Q000378:metabolism*; D010529:Peritoneal Cavity / Q000166:cytology; D010844:Picibanil / Q000494:pharmacology*; D011809:Quinones / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012717:Sesquiterpenes / Q000494:pharmacology
chemical_list: D001095:Arachidonic Acids; D001550:Benzamidines; D016227:Benzoquinones; D001688:Biological Products; D002630:Chemotactic Factors; D003169:Complement Inactivator Proteins; D006146:Guanidines; D008689:Methacrylates; D011809:Quinones; D012717:Sesquiterpenes; D010844:Picibanil; D004533:Egtazic Acid; C038797:K 76 carboxylic acid; D015936:Complement C5a; C036837:2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone; D004492:Edetic Acid; C034364:ozagrel; C032855:nafamostat